Life Technologies has decided to purchase AcroMetrix, a provider of molecular and serological diagnostic quality-control products to clinical laboratories, blood-screening centers, and in vitro diagnostic (IVD) manufacturers.
“With the growth of DNA and other molecular based tests, there is a growing need for high-quality, independently provided controls to ensure the accuracy and integrity of laboratory test results,” comments Gregory T. Lucier, chairman and CEO of Life Technologies.
“The addition of AcroMetrix will accelerate the expansion of our focused commercial channel for reaching molecular diagnostics customers, both with the current product portfolio and with assays in development,” adds Mark Stevenson, Life Technologies’ president and COO. “Our objective is to become the technology partner of choice to organizations worldwide that are building out their molecular diagnostic capabilities.”
Life Technologies’ portfolio of molecular diagnostics comprises more than $300 million of the company’s revenue, including components such as magnetic beads, fluorescent dyes, and specific antibodies that can be custom designed for diagnostic manufacturers. The company also provides the SPOT-Light® HER2 CISH Kit for assessment of breast cancer patients, the Dynachip® System for automated HLA antibody screening, and molecular diagnostic instruments such as the 3500 Dx Series Genetic Analyzer, cleared for diagnostic use in certain European countries. Additionally, the 7500 Fast and 7500 Fast Dx instruments have received emergency-use authorization from the FDA for surveillance of the H1N1 virus.